Status:
TERMINATED
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Lead Sponsor:
Ourotech, Inc.
Collaborating Sponsors:
Imperial College Healthcare NHS Trust
Conditions:
Brain Tumor
Glioma, Malignant
Eligibility:
All Genders
18+ years
Brief Summary
Pear Bio has developed a 3D microtumor assay and computer vision pipeline through which the response of an individual patient's tumor to different anti-cancer regimens can be tested simultaneously ex ...
Detailed Description
This is a multicenter, observational pilot study that aims to determine the feasibility of using the Pear Bio tool in patients with primary solid brain tumors. Patients who are due to undergo clinica...
Eligibility Criteria
Inclusion
- Inclusion:
- Patient diagnosed with operable brain cancer, thought likely to be primary solid brain tumor on imaging (grade 2 - 3 meningioma; grade 1 - 4 tumors otherwise) or with histologically proven primary malignant solid brain tumor
- Able to give written informed consent prior to admission to this study;
- Female or male aged ≥18 years;
- Patient consents to the use of their surgical sample and 40mL of whole blood for research purposes
- Surgical sample and yields ≥0.4g for the study
- Patient consents to providing histopathology data (e.g., confirmation of histological subtype as oligodendroglioma) and other pseudonymised health information including imaging, treatment and outcome data.
- Exclusion:
- Inoperable or biopsy only
- Suspected lymphoma or myeloma, or grade 1 meningioma
- Preoperative haemoglobin levels below 120g/L
- Patients who have already received chemotherapy, targeted therapy, immunotherapy, or radiotherapy less than 30 days before date of surgery, unless as part of a clinical trial (requires per-patient sponsor approval)
- Recurrence of cancer originating from a site other than the brain
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent.
Exclusion
Key Trial Info
Start Date :
October 12 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 25 2025
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06038760
Start Date
October 12 2023
End Date
July 25 2025
Last Update
July 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College Healthcare NHS Trust
London, United Kingdom, W6 8RF